Related Experiment Video

Updated: Mar 8, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders

C E Walsh1, K Workowski2, N A Terrault3

  • 1Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|January 27, 2017
PubMed

Insights

Hepatitis C virus (HCV) infection is effectively treated in patients with inherited bleeding disorders using ledipasvir-sofosbuvir or sofosbuvir plus ribavirin. These treatments demonstrated high efficacy and good tolerability in the study population.

Area of Science:

  • Hepatology
  • Virology
  • Hematology

Background:

  • Chronic hepatitis C virus (HCV) infection poses a significant mortality risk for individuals with inherited bleeding disorders, such as hemophilia.
  • Prevalence of HCV is notably high in this patient demographic.

Purpose of the Study:

  • To assess the efficacy and safety of ledipasvir-sofosbuvir and sofosbuvir plus ribavirin for treating chronic HCV genotypes 1-4 in patients with inherited bleeding disorders.
  • Evaluate treatment outcomes in a population with co-existing bleeding conditions and HCV.

Main Methods:

  • Ledipasvir-sofosbuvir was administered for 12 weeks to patients with HCV genotypes 1 or 4.
  • Treatment durations varied for cirrhotic patients with genotype 1 (12 or 24 weeks).
  • Sofosbuvir plus ribavirin was used for genotypes 2 (12 weeks) and 3 (24 weeks).

Main Results:

  • A sustained virologic response (SVR) at 12 weeks was achieved in 99% of patients with genotype 1 or 4, 100% with genotype 2, and 83% with genotype 3.
  • No patients discontinued treatment due to adverse events.
  • The majority of patients had severe bleeding disorders (55%), including hemophilia A (65%) and B (26%); 22% were HIV coinfected.

Conclusions:

  • Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin are highly effective treatments for HCV in patients with inherited bleeding disorders.
  • These antiviral regimens were well-tolerated, with minimal treatment-related adverse events, including bleeding events.
Abstract

Keywords:
NS5A inhibitorNS5B inhibitorhepatitis C virusledipasvir-sofosbuvir fixed-dose combinationribavirinsofosbuvir

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
7.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
702
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K